Study of Recombinant Antibody Fragments and PAI-1 Complexes Combining Protein-Protein Docking and Results from Site-Directed Mutagenesis (DOI:10.1016/j.str.2007.07.009);Study of Recombinant Antibody Fragments and PAI-1 Complexes Combining Protein-Protein Docking and Results from Site-Directed Mutagenesis

Structure

Volumn 15, Issue 9, 2007, Pages 1105-1116

  Novoa de Armas, Hector ^a   Dewilde, Maarten ^b   Verbeke, Koen ^b   De Maeyer, Marc ^b   Declerck, Paul J ^b  

^a DEPARTMENT OF PHARMACEUTICAL AND PHARMACOLOGICAL SCIENCES   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

PROTEINS

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY MA 56A7C10; MONOCLONAL ANTIBODY MA 8H9D4; NEUTRALIZING ANTIBODY; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECOMBINANT ANTIBODY; UNCLASSIFIED DRUG;

ALGORITHM; ARTICLE; CARDIOVASCULAR DISEASE; COMPLEX FORMATION; DIABETES MELLITUS; HEART INFARCTION; MOLECULAR DYNAMICS; MOLECULAR MODEL; MOLECULAR WEIGHT; OBESITY; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SITE DIRECTED MUTAGENESIS; TUMOR GROWTH; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM;

EID: 34548410760     PISSN: 09692126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.str.2007.09.002     Document Type: Erratum

References (86)

1. Aertgeerts K., De Bondt H.L., De Ranter C.J., and Declerck P.J. Mechanisms contributing to the conformational and functional flexibility of plasminogen activator inhibitor-1. Nat. Struct. Biol. 2 (1995) 891-897
2. Alessi M.C., Peiretti F., Morange P., Henry M., Nalbone G., and Juhan-Vague I. Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. Diabetes 46 (1997) 860-867
3. Al-Lazikani B., Lesk A.M., and Chothia C. Standard conformations for the canonical structures of immunoglobulins. J. Mol. Biol. 273 (1997) 927-948
4. Berchanski A., Shapira B., and Eisenstein M. Hydrophobic complementarity in protein-protein docking. Proteins 56 (2004) 130-142
5. Berman H.M., Westbrook J., Feng Z., Gilliland G., Bhat T.N., Weissig H., Shindyalov I.N., and Bourne P.E. The Protein Databank. Nucleic Acids Res. 28 (2000) 235-242
6. Berry C.N., Lunven C., Lechaire I., Girardot C., and O'Connor S.E. Antithrombotic activity of a monoclonal antibody inducing the substrate form of plasminogen activator inhibitor type 1 in rat models of venous and arterial thrombosis. Br. J. Pharmacol. 25 (1998) 29-34
7. Bijnens A.P., Gils A., Stassen J.M., Komissarov A.A., Knockaert I., Brouwers E., Shore J.D., and Declerck P.J. The distal hinge of the reactive site loop and its proximity: a target to modulate plasminogen activator inhibitor-1 activity. J. Biol. Chem. 276 (2001) 44912-44918
8. Bjorquist P., Ehnebom J., Inghardt T., Hansson L., Lindberg M., Linschoten M., Stromqvist M., and Deinum J. Identification of the binding site for a low-molecular-weight inhibitor of plasminogen activator inhibitor type 1 by site-directed mutagenesis. Biochemistry 37 (1998) 1227-1234
9. Brooks B.R., Bruccoleri R.E., Olafson B.D., States D.J., Swaminathan S., and Karplus M. CHARMM: a program for macromolecular energy, minimization, and dynamics calculations. J. Comput. Chem. 4 (1983) 187-217
10. Bruccoleri R.E., and Karplus M. Prediction of the folding of short polypeptide segments by uniform conformational sampling. Biopolymers 26 (1987) 137-168
11. Brünger A.T., Adams P.D., Clore G.M., DeLano W.L., Gros P., Grosse-Kunstleve R.W., Jiang J.S., Kuszewski J., Nilges M., Pannu N.S., et al. Crystallography & NMR system: a new software suite for macromolecular structure determination. Acta Crystallogr. D Biol. Crystallogr. 54 (1998) 905-921
12. Camacho C.J., and Gatchell D.W. Successful discrimination of protein interactions. Proteins 52 (2003) 92-97
13. Camacho C.J., Gatchell D.W., Kimura S.R., and Vajda S. Scoring docked conformations generated by rigid-body protein-protein docking. Proteins 40 (2000) 525-537
14. Charlton P.A., Faint R.W., Bent F., Bryans J., Chicarelli-Robinson I., Mackie I., Machin S., and Bevan P. Evaluation of a low molecular weight modulator of human plasminogen activator inhibitor-1 activity. Thromb. Haemost. 75 (1996) 808-815
15. Charlton P.A., Faint R.W., Barnes C., Bent F., Folkes A., Templeton D., Mackie I., Machin S., and Bevan P. XR5118, a novel modulator of plasminogen activator inhibitor-1 (PAI-1), increases endogenous tPA activity in the rat. Fibrinolysis & Proteolysis 11 (1997) 51-56
16. Chen R., Li L., and Weng Z. ZDOCK: an initial-stage protein docking algorithm. Proteins 52 (2003) 80-87
17. Chen R., Tong W., Mintseris J., Li L., and Weng Z. ZDOCK predictions for the CAPRI challenge. Proteins 52 (2003) 68-73
18. Chothia C., Lesk A.M., Tramontano A., Levitt M., Smith-Gill S.J., Air G., Sheriff S., Padlan E.A., Davies D., and Tulip W.R. Conformations of immunoglobulin hypervariable regions. Nature 342 (1989) 877-883
19. Comeau S.R., Gatchell D.W., Vajda S., and Camacho C.J. ClusPro: an automated docking and discrimination method for the prediction of protein complexes. Bioinformatics 20 (2004) 45-50
20. Comeau S.R., Vajda S., and Camacho C.J. Performance of the first docking server ClusPro in CAPRI runds 3-5. Proteins 60 (2005) 239-244
21. Crandall D.L., Quinet E.M., El A.S., Hreha A.L., Leik C.E., Savio D.A., Juhan-Vague I., and Alessi M.C. Modulation of adipose tissue development by pharmacological inhibition of PAI-1. Arterioscler. Thromb. Vasc. Biol. 26 (2006) 2209-2215
22. Davies D.R., and Cohen G.H. Interactions of protein antigens with antibodies. Proc. Natl. Acad. Sci. USA 93 (1996) 7-12
23. Debrock S., and Declerck P.J. Neutralization of plasminogen activator inhibitor-1 inhibitory properties: identification of two different mechanisms. Biochim. Biophys. Acta 1337 (1997) 257-266
24. Debrock S., Sironi L., and Declerck P.J. Cloning of a single-chain variable fragment (scFv) switching active plasminogen activator inhibitor-1 to substrate. Gene 189 (1997) 83-88
25. Declerck P.J., and Collen D. Measurement of plasminogen activator inhibitor 1 (PAI-1) in plasma with various monoclonal antibody-based enzyme-linked immunosorbent assays. Throm. Res. Suppl. 10 (1990) 3-9
26. Declerck P.J., De Mol M., Vaughan D.E., and Collen D. Identification of a conformationally distinct form of plasminogen activator inhibitor-1, acting as noninhibitory substrate for tissue-type plasminigen activator. J. Biol. Chem. 267 (1992) 11693-11696
27. Delhaise P., Bardiaux M., De Maeyer M., Prevost M., Van Belle D., Donneux J., Lasters I., Van Custem E., Alard P., and Wodak S. The Brugel package-toward computer-aided-design of macromolecules. J. Mol. Graph. 6 (1998) 219
28. Desmet J., De Maeyer M., Haze B., and Lasters I. The dead-end elimination theorem and its use in protein side-chain positioning. Nature 356 (1992) 539-542
29. Desmet J., Meersseman G., Boutonnet N., Pletinckx J., De Clercq K., Debulpaep M., Braeckman T., and Lasters I. Anchor profiles of HLA-specific peptides: analysis by a novel affinity scoring method and experimental validation. Proteins 58 (2005) 53-69
30. De Taeye B., Gils A., Vleugels N., Rabijns A., and Declerck P.J. Comparative analysis of the proteinase specificity in wild-type and stabilized plasminogen activator inhibitor-1: evidence for contribution of intramolecular flexibility. Biochem. Biophys. Res. Commun. 321 (2004) 746-751
31. De Taeye B., Compernolle G., and Declerck P.J. Site-directed targeting of Plasminogen Activator Inhibitor-1 as an example for a novel approach in rational drug design. J. Biol. Chem. 279 (2004) 20447-20450
32. Dominguez C., Boelens R., and Bonvin A.M. HADDOCK: a protein-protein docking approach based on biochemical or biophysical information. J. Am. Chem. Soc. 125 (2003) 1731-1737
33. Durand M.K.V., Bødker J.S., Christensen A., Dupont D.M., Hansen M., Jensen J.K., Kjelgaard S., Mathiasen L., Pedersen K.E., Skeldal S., et al. Plasminogen activator inhibitor-1 and tumour growth, invasion, and metastasis. Thromb. Haemost. 91 (2004) 438-449
34. Elokdah H., Abou-Gharbia M., Hennan J.K., McFarlane G., Mugford C.P., Krishnamurthy G., and Crandall D.L. Tiplaxtinin, a novel, orally efficacious inhibitor of plasminogen activator inhibitor-1: design, synthesis, and preclinical characterization. J. Med. Chem. 47 (2004) 3491-3494
35. Fernandez-Recio J., Totrov M., and Abagyan R. ICM-DISCO docking by global energy optimization with fully flexible side-chains. Proteins 52 (2003) 113-117
36. Folkes A., Roe M.B., Sohal S., Golec J., Faint R., Brooks T., and Charlton P. Synthesis and in vitro evaluation of diketopiperazine inhibitors of plasminogen activator inhibitor-1. Bioorg. Med. Chem. Lett. 11 (2001) 2589-2592
37. Gils A., and Declerck P.J. The structural basis for the pathophysiological relevance of PAI-1 in cardiovascular diseases and the development of potential PAI-1 inhibitors. Thromb. Haemost. 91 (2004) 425-437
38. Gils A., Stassen J.M., Nar H., Kley J.T., Wienen W., Ries U.J., and Declerck P.J. Characterization and comparative evaluation of a novel PAI-1 inhibitor. Thromb. Haemost. 88 (2002) 137-143
39. Gray J.J., Moughon S.E., Wang C., Schueler-Furman O., Misura K.M., Morozov A.V., and Baker D. Protein-protein docking with simultaneous optimization of rigid body displacement and side-chain conformations. J. Mol. Biol. 331 (2003) 281-299
40. Hekman C.M., and Loskutoff D.J. Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants. J. Biol. Chem. 260 (1985) 11581-11587
41. Hekman C.M., and Loskutoff D.J. Bovine plasminogen activator inhibitor 1: specificity determinations and comparison of the active, latent, and guanidine-activated forms. Biochemistry 19 (1988) 2911-2918
42. Huber R., and Carrel R.W. Implications of the three-dimensional structure of α1-antitrypsin for the structure and functions of serpins. Biochemistry 28 (1989) 8951-8966
43. Janin J., Miller S., and Chothia C. Surface, subunit interfaces and interior of oligomeric proteins. J. Mol. Biol. 204 (1988) 155-164
44. Janin J., Henrick K., Moult J., Eyck L., Sternberg M., Vajda S., Vakser I., and Wodak S. CAPRI: a critical assessment of predicted interactions. Proteins 52 (2003) 2-9
45. Jones D.T., and Thornton J.M. Principles of protein-protein interactions. Proc. Natl. Acad. Sci. USA 93 (1996) 13-20
46. Keijer J., Linders M., van Zonneveld A.J., Ehrlich H.J., de Boer J.P., and Pannekoek H. The interaction of plasminogen activator inhibitor 1 with plasminogen activators (tissue-type and urokinase-type) and fibrin: localization of interaction sites and physiologic relevance. Blood 78 (1991) 401-409
47. Laskowski R.A. SURFNET: a program for visualizing molecular surfaces, cavities and intermolecular interactions. J. Mol. Graph. 13 (1995) 323-330
48. Laskowski R.A., MacArthur M.W., Moss D.S., and Thornton J.M. PROCHECK - a program to check the stereochemical quality of protein structures. J. Appl. Cryst. 26 (1993) 283-291
49. Lee B.K., and Richards F.M. The interpretation of protein structures: estimation of static accessibility. J. Mol. Biol. 55 (1971) 379-400
50. Li L., Chen R., and Weng Z.P. RDOCK: refinement of rigid body protein docking predictions. Proteins 53 (2003) 693-707
51. Lijnen H.R., Alessi M.C., Van H.B., Collen D., and Juhan-Vague I. On the role of plasminogen activator inhibitor-1 in adipose tissue development and insulin resistance in mice. J. Thromb. Haemost. 3 (2005) 1174-1179
52. Lo Conte L., Chotia C., and Janin J. The atomic structure of protein-protein recognition sites. J. Mol. Biol. 285 (1999) 2177-2198
53. MacGregor I.R., Tonner A.M., Mickelm L.R., James K., and Booth N.A. Murine monoclonal antibodies against active site epitopes on human endothelial plasminogen activator inhibitor (PAI-1). Fibrinolysis 4 (1990) 27-34
54. Mandell J.G., Roberts V.A., Pique M.E., Kotlovyi V., Mitchell J.C., Nelson E., Tsigelny I., and Ten Eyck L.F. Protein docking using continuum electrostatics and geometric fit. Protein Eng. 14 (2001) 105-113
55. Martin A.C.R., Cheetham J.C., and Rees A.R. Modeling antibody hypervariable loops: a combined algorithm. Proc. Natl. Acad. Sci. USA 86 (1989) 9268-9272
56. Martin A.C.R., Cheetham J.C., and Rees A.R. Molecular modelling of antibody combining sites. Methods Enzymol. 203 (1991) 121-153
57. Montes R., Declerck P.J., Calvo A., Montes M., Hermida J., Munoz M.C., and Rocha E. Prevention of renal fibrin deposition in endotoxin-induced DIC through inhibition of PAI-1. Thromb. Haemost. 84 (2000) 65-70
58. H domain of immunoglobulins. J. Mol. Biol. 275 (1998) 269-294
59. Mottonen J., Strand A., Symersky J., Sweet R.M., Danley D.E., Geoghegan K.F., Gerard R.D., and Goldsmith E.J. Structural basis of latency in plasminogen activator inhibitor-1. Nature 355 (1992) 270-273
60. Munch M., Heegaard C.W., and Andreasen P.A. Interconversions between active, inert and substrate forms of denaturated/refolded type-1 plasminogen activator inhibitor. Biochim. Biophys. Acta 1202 (1993) 29-37
61. Naessens D., Gils A., Compernolle G., and Declerck P.J. Elucidation of a novel epitope of a substrate-inducing monoclonal antibody against the serpin PAI-1. J. Thromb. Haemost. 1 (2003) 1028-1033
62. Nar H., Bauer M., Stassen J.M., Lang D., Gils A., and Declerck P.J. Plasminogen activator inhibitor 1. Structure of the native serpin, comparison to its other conformers and implications for serpin inactivation. J. Mol. Biol. 297 (2000) 683-695
63. Nielsen L.S., Andreasen P.A., Grondahl H.J., Huang J.Y., Kristensen P., and Dano K. Monoclonal antibodies to human 54,000 molecular weight plasminogen activator inhibitor from fibrosarcoma cells-inhibitor neutralization and one-step affinity purification. Thromb. Haemost. 55 (1986) 206-212
64. Nordt T.K., Sawa H., Fujii S., Bode C., and Sobel B.E. Augmentation of arterial endothelial cell expression of the plasminogen activator inhibitor type-1 (PAI-1) gene by proinsulin and insulin vivo. J. Mol. Cell. Cardiol. 30 (1998) 1535-1543
65. Pawlowska Z., Chabielska E., Kobylanska A., Maciaszek A., Swiatkowska M., Buczko W., Stec W.J., and Cierniewski C.S. Regulation of PAI-1 concentration in platelets by systemic administration of antisense oligonucleotides to rats. Thromb. Haemost. 85 (2001) 1086-1089
66. Pedersen J., Searle S., Henry A.H., and Rees A.R. Antibody modelling: beyond homology. Immunomethods 1 (1992) 126-136
67. Pettersen E.F., Goddard T.D., Huang C.C., Couch G.S., Greenblatt D.M., Meng E.C., and Ferrin T.E. UCSF Chimera - a visualization system for exploratory research and analysis. J. Comput. Chem. 25 (2004) 1605-1612
68. Robbie L.A., Booth N.A., Brown A.J., and Bennett B. Inhibitors of fibrinolysis are elevated in atherosclerotic plaque. Arterioscler. Thromb. Vasc. Biol. 16 (1996) 539-545
69. Rupin A., Martin F., Vallez M.O., Bonhomme E., and Verbeuren T.J. Inactivation of plasminogen activator inhibitor-1 accelerates thrombolysis of a platelet-rich thrombus in rat mesenteric arterioles. Thromb. Haemost. 86 (2001) 1528-1531
70. Schafer K., Fujisawa K., Konstantinides S., and Loskutoff D.J. Disruption of the plasminogen activator inhibitor 1 gene reduces the adiposity and improves the metabolic profile of genetically obese and diabetic ob/ob mice. FASEB J. 15 (2001) 1840-1842
71. Schulman S., and Wiman B. The significance of hypofibrinolysis for the risk of recurrence of venous thromboembolism. Duration of Anticoagulation (DURAC) Trial Study Group. Thromb. Haemost. 75 (1996) 607-611
72. Sharp A.M., Stein P.E., Pannu N.S., Carrel R.W., Bekenpas M.B., Ginsburg D., Lawrence D.A., and Read R. The active conformation of plasminogen activator inhibitor 1, a target for drugs to control fibrinolysis and cell adhesion. Structure 7 (1999) 111-118
73. Shirai H., Kidera A., and Nakamura H. Structural classification of CDR-H3 in antibodies. FEBS Lett. 399 (1996) 1-8
74. Shirai H., Kidera A., and Nakamura H. H3-rules: identification of CDR-H3 structures in antibodies. FEBS Lett. 455 (1999) 188-197
75. Smith L.H., Dixon J.D., Stringham J.R., Eren M., Elokdah H., Crandall D.L., Washington K., and Vaughan D.E. Pivotal role of PAI-1 in a murine model of hepatic vein thrombosis. Blood 107 (2006) 132-134
76. Staelens S., Desmet J., Ngo T.H., Vauterin S., Pareyn I., Barbeaux P., Van Rompaey I., Stassen J.M., Deckmyn H., and Vanhoorelbeke K. Humanization by variable domain resurfacing and grafting on a human IgG4, using a new approach for determination of non-human like surface accessible framework residues based on homology modelling of variable domains. Mol. Immunol. 43 (2006) 1243-1257
77. Staelens S., Hadders M.A., Vauterin S., Platteau C., De Maeyer M., Vanhoorelbeke K., Huizinga E.G., and Deckmyn H. Paratope determination of the antithrombotic antibody 82D6A3 based on the crystal structure of its complex with the von Willebrand factor A3-domain. J. Biol. Chem. 281 (2006) 2225-2231
78. Ten Eyck, L.F., Mandell, J., Roberts, V.A., and Pique, M.E. (1995). Surveying molecular interactions with DOT. Proceedings of the 1995 ACM/IEEE Supercomputing Conference, A. Hayes, and M. Simmons, eds. (New York: ACM Press).
79. van Dijk A.D.J., Boelens R., and Bonvin A.M.J.J. Data-driven docking for the study of biomolecular complexes. FEBS J. 272 (2005) 293-312
80. van Giezen J.J., Wahlund G., Nerme, and Abrahamson T. The Fab-fragment of a PAI-1 inhibiting antibody reduces thrombus size and restores blood flow in a rat model of arterial thrombosis. Thromb. Haemost. 77 (1997) 964-969
81. Verbeke K., Gils A., Stassen J.M., and Declerck P.J. Elucidation of the paratope of scFv-8H9D4, a PAI-1 neutralizing antibody derivative. Thromb. Haemost. 89 (2003) 74-82
82. Verbeke K., Gils A., and Declerck P.J. Cloning and paratope analysis of an antibody fragment, a rational approach for the design of a PAI-1 inhibitor. J. Thromb. Haemost. 2 (2004) 289-297
83. Vinogradsky B., Bell S.P., Woodcock-Mitchell J., Ohtani A., and Fujii S. A new butadiene derivative, T-686, inhibits plasminogen activator inhibitor type-1 production in vitro by cultured human vascular endothelial cells and development of atherosclerotic lesions in vivo in rabbits. Thromb. Res. 85 (1997) 305-314
84. Wang C., Schueler-Furman O., and Baker D. Improved side-chain modeling for protein-protein docking. Protein Sci. 14 (2005) 1328-1339
85. Webster D.M., Henry A.H., and Rees A.R. Antibody-antigen interactions. Curr. Opin. Struct. Biol. 4 (1994) 123-129
86. Whitelegg N.R., and Rees A.R. WAM: an improved algorithm for modeling antibodies on the WEB. Protein Eng. 13 (2000) 819-824